![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://investors.aeriepharma.com/news-releases/news-release-details/aerie-concludes-exclusive-license-agreement-santen-rhopressar
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2020
https://investors.aeriepharma.com/news-releases/news-release-details/aerie-pharmaceuticals-receives-positive-chmp-opinion-roclandar#:~:text=Aerie%20Pharmaceuticals%20Receives%20Positive%20CHMP%20Opinion%20for%20Roclanda%C2%AE%20in%20the%20European%20Union,-11%2F13%2F2020&text=DURHAM%2C%20N.C.&text=The%20CHMP%20positive%20opinion%20is,decision%20on%20the%20Company's%20MAA.
https://www.businesswire.com/news/home/20200915005132/en/Aerie-Pharmaceuticals-Announces-U.S.-Food-and-Drug-Administration-Approval-of-its-Athlone-Ireland-Facility-for-Production-of-Rhopressa%C2%AE-netarsudil-ophthalmic-solution-0.02
https://www.businesswire.com/news/home/20191203005049/en/Aerie-Pharmaceuticals-Submits-Marketing-Authorisation-Application-Roclanda%C2%AE/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==
https://www.clinicaltrialsarena.com/news/aerie-phaseii-netarsudil-study-data/
https://seekingalpha.com/news/3514317-medical-properties-trust-buy-10-hospitals-700m
https://www.businesswire.com/news/home/20191105005217/en/Aerie-Pharmaceuticals-Announces-Positive-Topline-Results-Netarsudil/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==
http://www.pharmatimes.com/news/xospata_leads_latest_chmp_recommendations_1302120
https://www.raps.org/news-and-articles/news-articles/2019/9/emas-chmp-recommends-three-new-medicines
https://www.fiercebiotech.com/biotech/aerie-adds-vargas-once-abbott-to-medical-affairs-team
https://endpts.com/less-than-a-year-after-rhopressa-launch-aerie-scores-new-glaucoma-drug-approval/
http://investors.aeriepharma.com/news-releases/news-release-details/aerie-pharmaceuticals-reports-topline-result-rhopressar
http://investors.aeriepharma.com/news-releases/news-release-details/aerie-pharmaceuticals-announces-early-notification-fda
http://investors.aeriepharma.com/news-releases/news-release-details/aerie-pharmaceuticals-submits-new-drug-application-us-food-and-0
https://www.businesswire.com/news/home/20180430005006/en/Aerie-Pharmaceuticals-Announces-U.S.-Launch-Rhopressa%C2%AE-netarsudil
http://investors.aeriepharma.com/news-releases/news-release-details/aerie-pharmaceuticals-announces-us-launch-rhopressar-netarsudil
http://www.pmlive.com/pharma_news/fdas_year-end_approvals_take_annual_tally_to_46_1215003
https://endpts.com/aerie-bags-an-early-ok-for-its-self-described-blockbuster-glaucoma-drug-rhopressa/
http://investors.aeriepharma.com/static-files/d78e4f47-803b-4174-8f89-ddcc200e3972
http://investors.aeriepharma.com/news-releases/news-release-details/aerie-pharmaceuticals-announces-us-fda-approval-rhopressar